DUBLIN–(BUSINESS WIRE)–The “Global
Uveitis Clinical Trial Pipeline Highlights – 2019” report has
been added to ResearchAndMarkets.com’s offering.
Uveitis Pipeline Highlights – 2019, provides the most
up-to-date information on key pipeline products in the global uveitis
market. It covers emerging therapies for uveitis in active clinical
development stages including early and late stage clinical trials. The
pipeline data presented in this report helps executives in tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.
Clinical Trial Stages:
The report provides uveitis pipeline products by clinical trial stages
including both early and late stage development – phase 3 clinical
trials, phase 2 clinical trials, phase 1 clinical trials, preclinical
research, and discovery stage.
Drug Mechanism Classes:
The report provides uveitis pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.
Company:
The report provides uveitis pipeline products by the company.
Short-term Launch Highlights:
Find out which uveitis pipeline products will be launched in the US and
Ex-US to 2024.
Key Topics Covered:
1. Uveitis Pipeline by Stages
2. Uveitis Phase 3 Clinical Trial Insights
3. Uveitis Phase 2 Clinical Trial Insights
4. Uveitis Phase 1 Clinical Trial Insights
5. Uveitis Preclinical Research Insights
6. Uveitis Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/c8epuy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Clinical
Trials, Optical
Disorders Drugs